Drugs / DUVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07142278 | Nov 2025 → Apr 2027 expected | Alzheimer disease | Nuravax, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DUVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07142278 ↗ |
| Modality | Vaccine | “This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults.” NCT07142278 ↗ |
| Route | Intramuscular | “Participants will receive three intramuscular doses at Weeks 0, 4, and 22.” NCT07142278 ↗ |